Avalyn Pharma Inc.

Avalyn Pharma Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing inhaled therapies for rare respiratory diseases. Its pipeline centers on nebulizer-delivered product candidates for progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, and other interstitial lung diseases, supported by licensed device technology and third-party manufacturing.

— Avalyn Pharma Inc.
%
Lead clinical candidates0% Nebulized drug candidates AP01 and AP02 being developed for rare respiratory diseases.
Pipeline discovery and preclinical programs0% Additional product candidates under discovery and early development.
Drug-device combination platform0% Inhalation delivery approach built around licensed nebulizer technology and accessories.
Intellectual property and licensing0% Licensed and owned IP supporting development and future commercialization rights.

Avalyn does not yet sell approved products; its near-term counterparties are clinical trial sites, contract...

  • Clinical trial sites and investigatorsprimary

    They run the studies for AP01, AP02, and future candidates and are essential to generating clinical evidence.

  • Contract manufacturing organizationsprimary

    They manufacture clinical and future commercial supply for the inhaled product candidates.

  • Regulatory authoritiesprimary

    FDA, EMA, and comparable agencies review the drug-device combination and determine approval timing.

  • Future specialty prescribers and care centerssecondary

    Pulmonologists and specialty centers would prescribe approved therapies for rare fibrotic lung diseases.

  • Payers and reimbursement decision-makerssecondary

    They would determine coverage and access for any approved product in rare respiratory diseases.

Avalyn is headquartered in the United States and operates as a U.S.-based development company, but its clinical work...

  • •Headquartered in the United States
  • •Clinical development may include foreign trial sites
  • •FDA and EMA oversight are relevant to approval pathways
  • •No commercial geography yet because products are not approved
  • •Future commercialization would depend on market access and reimbursement

Avalyn’s strategy is to advance AP01, AP02, and additional inhaled candidates through clinical development and...

01
Complete clinical development of AP01 and AP02short-term

Clinical proof is required before any regulatory filing or commercialization can occur.

02
Secure regulatory approvals for combination productsmedium-term

Nebulizer-delivered therapies require coordinated review of drug and device components.

03
Build manufacturing and commercial readinessmedium-term

Approved products will need reliable supply, distribution, and market access infrastructure.

04
Preserve and expand intellectual propertylong-term

Patent and license protection support exclusivity and future value creation.

Avalyn faces the typical risks of a clinical-stage biotech company: long development timelines, uncertain trial...

high

Need for additional capital

The company has no product revenue and must fund clinical and pre-commercial work for years.

Scope
Development programs and corporate operations
Materiality
high
high

Clinical trial failure or delay

AP01 and AP02 must show safety and efficacy before approval can be sought.

Scope
Lead pipeline candidates
Materiality
high
medium

Combination product regulatory complexity

Nebulizer-delivered therapies require review of both drug and device components.

Scope
AP01, AP02, and future inhaled candidates
Materiality
high
medium

Third-party manufacturing dependence

External manufacturers may fail to supply material at acceptable quality, cost, or timing.

Scope
Clinical and future commercial supply
Materiality
high
medium

Foreign trial execution risk

International studies can face translation, protocol adherence, and political/regulatory issues.

Scope
Clinical development outside the U.S.
Materiality
medium
medium

Intellectual property and licensing risk

The business depends on maintaining licensed rights and defending patents.

Scope
PARI license and broader IP portfolio
Materiality
high
Research and development accruals
R&D expense and accrued liabilities
Equity financing and IPO accounting
Cash, additional paid-in capital, and share count
License and royalty obligations
Operating expenses and contingent obligations
Emerging growth company accounting elections
Disclosure comparability and timing of standard adoption

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

ALNYLAM PHARMACEUTICALS, INC.

ALNY · Pharmaceutical Preparations

CytoDyn Inc.

CYDY · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

Apellis Pharmaceuticals, Inc.

Pharmaceutical Preparations

Avidity Biosciences, Inc.

Pharmaceutical Preparations

: 11/08/2026